February 5 next meeting of the Transparency Council.
During the session, preparation was planned:
- Positions on the qualification of the service "Repositioning and immobilization of a dislocated tooth or group of teeth and removal of a dental splint when replacing or completing treatment" as a guaranteed benefit.
- Positions on the evaluation of the drug Keytruda (pembrolizumabum) under the drug program "Treatment of patients with cervical cancer (ICD-10: C53)".
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
